ArticleCureus2025
Refractory Ulcerative Colitis Successfully Treated With a Combination of Granulocyte and Monocyte Apheresis and Mirikizumab: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report the case of a 42-year-old man with treatment-refractory ulcerative colitis (UC), complicated by steroid dependence, adverse effects of immunomodulators, and significant social limitations, including inability to be hospitalized or take oral medications. Granulocyte and monocyte adsorptive apheresis (GMA) was initiated as an induction therapy, followed by the addition of mirikizumab, an anti-IL-23p19 monoclonal antibody. This sequential combination therapy resulted in significant clinical improvement and endoscopic mucosal healing. A detailed breakdown of the clinical course, objective disease activity markers, and colonoscopic findings is provided to illustrate the rationale and effectiveness of this approach. This case suggests that a stepwise treatment strategy combining GMA and biologics may be effective in managing treatment-refractory UC with complex clinical backgrounds. To our knowledge, this is the first reported case demonstrating the effectiveness of combination therapy with GMA and mirikizumab in UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.